GeoVax LabsGOVX
Market Cap: $23M
About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
29% more capital invested
Capital invested by funds: $481K [Q1] → $619K (+$138K) [Q2]
9% more funds holding
Funds holding: 11 [Q1] → 12 (+1) [Q2]
3.42% less ownership
Funds ownership: 11.1% [Q1] → 7.68% (-3.42%) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Noble Capital Markets Robert LeBoyer 50% 1-year accuracy 2 / 4 met price target | 270%upside $10 | Outperform Maintained | 19 Aug 2024 |
EF Hutton Jason Kolbert 49% 1-year accuracy 17 / 35 met price target | 567%upside $18 | Buy Maintained | 19 Aug 2024 |
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 18 / 49 met price target | 196%upside $8 | Buy Reiterated | 12 Aug 2024 |
EF Hutton Jason Kolbert 49% 1-year accuracy 17 / 35 met price target | 567%upside $18 | Buy Maintained | 7 Aug 2024 |
EF Hutton Jason Kolbert 49% 1-year accuracy 17 / 35 met price target | 567%upside $18 | Buy Initiated | 23 Jul 2024 |
Financial journalist opinion
Based on 3 articles about GOVX published over the past 30 days